MA31080B1 - Dérivés cyclisés en tant qu'inhibiteurs d'eg-5. - Google Patents

Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.

Info

Publication number
MA31080B1
MA31080B1 MA32061A MA32061A MA31080B1 MA 31080 B1 MA31080 B1 MA 31080B1 MA 32061 A MA32061 A MA 32061A MA 32061 A MA32061 A MA 32061A MA 31080 B1 MA31080 B1 MA 31080B1
Authority
MA
Morocco
Prior art keywords
cycled
inhibitors
derivatives
pharmaceutically acceptable
prodrugs
Prior art date
Application number
MA32061A
Other languages
English (en)
Inventor
Rustum Boyce
Eric Martin
Weibo Wang
Hong Yang
Paul A Barsanti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31080B1 publication Critical patent/MA31080B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS D'IMIDAZOLE SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I) CI-DESSOUS ET LEURS SELS, ESTERS ET PROMÉDICAMENTS PHARMACEUTIQUEMENT ACCEPTABLES, DES COMPOSITIONS DES COMPOSÉS ACCOMPAGNÉS DE VECTEURS PHARMACEUTIQUEMENT ACCEPTABLES ET LES UTILISATIONS DES COMPOSÉS : (I).
MA32061A 2007-01-05 2009-06-30 Dérivés cyclisés en tant qu'inhibiteurs d'eg-5. MA31080B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88374007P 2007-01-05 2007-01-05

Publications (1)

Publication Number Publication Date
MA31080B1 true MA31080B1 (fr) 2010-01-04

Family

ID=39577804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32061A MA31080B1 (fr) 2007-01-05 2009-06-30 Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.

Country Status (30)

Country Link
US (3) US7820646B2 (fr)
EP (1) EP2106399A2 (fr)
JP (1) JP2010515687A (fr)
KR (1) KR20090097210A (fr)
CN (1) CN101622247A (fr)
AR (1) AR064760A1 (fr)
AU (1) AU2008205169B2 (fr)
BR (1) BRPI0806264A2 (fr)
CA (1) CA2674318A1 (fr)
CL (1) CL2008000029A1 (fr)
CO (1) CO6561828A2 (fr)
CR (1) CR10879A (fr)
DO (1) DOP2009000169A (fr)
EA (1) EA200900924A1 (fr)
EC (1) ECSP099485A (fr)
GE (1) GEP20125415B (fr)
GT (1) GT200900192A (fr)
HN (1) HN2009001262A (fr)
MA (1) MA31080B1 (fr)
MX (1) MX2009007260A (fr)
NI (1) NI200900134A (fr)
NZ (1) NZ577727A (fr)
PE (1) PE20081850A1 (fr)
SM (1) SMP200900065B (fr)
SV (1) SV2009003325A (fr)
TN (1) TN2009000287A1 (fr)
TW (1) TW200836722A (fr)
UA (1) UA97821C2 (fr)
WO (1) WO2008086122A2 (fr)
ZA (1) ZA200904175B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
WO2011128388A2 (fr) * 2010-04-15 2011-10-20 Novartis Ag Composés d'oxazole et de thiazole comme inhibiteurs de ksp
EP2558450A1 (fr) 2010-04-15 2013-02-20 Novartis AG Composés de triazole comme inhibiteurs de la ksp
EP2390247A1 (fr) * 2010-05-26 2011-11-30 Netherlands Organisation for Scientific Research (Advanced Chemical Technologies for Sustainability) Préparation de caprolactone, caprolactam, 2,5-tétrahydrofuranne diméthanol, 1,6-héxanediol ou 1,2,6-hexanetriol à partir de 5-hydroxymethyl-2-furfuraldehyde
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
EP2968591A1 (fr) * 2013-03-15 2016-01-20 Novartis AG Inhibiteurs de la prolifération cellulaire et leurs conjugués
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
AU2014372833B2 (en) * 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
SG11201710639YA (en) * 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105367506B (zh) * 2015-12-08 2021-02-05 华润双鹤药业股份有限公司 手性高哌嗪环的制备方法
CN105330657B (zh) * 2015-12-08 2019-05-21 华润双鹤药业股份有限公司 5-氯-2-[5-(r)-甲基-1,4-二氮杂环庚烷-1-]苯并恶唑的制备方法
WO2017216028A1 (fr) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
CA3103327A1 (fr) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Conjugues d'agent liant-principe actif inhibant cxcr5 comprenant des elements de liaison pouvant etre fragmentes de maniere enzymatique et presentant un profil d'action ameliore
CN119859151B (zh) * 2023-10-19 2026-07-24 北京振东光明药物研究院有限公司 从白土苓中分离得到的生物碱类化合物及其制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (de) 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB2157285B (en) 1984-04-11 1987-10-28 Erba Farmitalia 1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5859012A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0946587A2 (fr) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amide
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
CA2369549A1 (fr) 1999-04-02 2000-10-12 Robert W. Desimone Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
EP1226129B1 (fr) 1999-10-27 2006-05-24 Cytokinetics, Inc. Procedes et compositions utilisant des quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001227812A1 (en) 2000-05-02 2001-11-12 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
US6683191B2 (en) 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
AU2001264872A1 (en) 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
US20030055037A1 (en) 2000-10-06 2003-03-20 Delombaert Stephane Benzimidazole and indole derivatives as CRF receptor modulators
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
EP1360180A1 (fr) 2001-01-19 2003-11-12 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
CA2465491A1 (fr) 2001-11-07 2003-05-15 Merck & Co., Inc. Inhibiteurs de la kinesine mitotique
AU2002346471A1 (en) 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
CA2467916A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs miotitiques de la kinesine
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
WO2003050122A2 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
WO2003059289A2 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
EP1492487B1 (fr) 2002-03-08 2009-11-11 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP4664597B2 (ja) 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
US7030144B2 (en) 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
CA2484936A1 (fr) 2002-05-08 2004-05-21 Neurogen Corporation Imidazolylmethyl pyridine substituee et derives de pyrazine: les ligands des recepteurs gaba<sb>a</sb>
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
JP2006502974A (ja) 2002-05-17 2006-01-26 ニューロジェン コーポレイション 置換環縮合イミダゾール誘導体：ｇａｂａａ受容体リガンド
JP2005530806A (ja) * 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
WO2003103575A2 (fr) 2002-05-23 2003-12-18 Cytokinetics, Inc. Composes, compositions et procedes
IL165624A0 (en) 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
AU2003276005B2 (en) 2002-06-14 2009-01-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2489367A1 (fr) 2002-06-14 2003-12-24 Cytokinetics, Inc. Composes, compositions et procedes
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
ATE423110T1 (de) 2002-07-17 2009-03-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004009036A2 (fr) 2002-07-23 2004-01-29 Cytokinetics, Inc. Composes, compositions et procedes
EP1539180A4 (fr) 2002-08-21 2006-08-30 Cytokinetics Inc Composes, compositions et methodes
WO2004024086A2 (fr) 2002-09-13 2004-03-25 Cytokinetics, Inc. Composés, compositions et méthodes
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
DE60307499T2 (de) 2002-11-08 2007-02-01 Neurogen Corp., Branford 4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
WO2004055008A1 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Composes, compositions et methodes
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
EP1620092A4 (fr) 2003-05-07 2008-04-16 Cytokinetics Inc Composes, compositions et methodes
WO2004103282A2 (fr) 2003-05-15 2004-12-02 Cytokinetics, Inc. Composes, compositions et procedes
ES2339862T3 (es) 2003-06-20 2010-05-26 Novartis Vaccines And Diagnostics, Inc. Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos.
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
WO2005080346A1 (fr) 2004-02-12 2005-09-01 Transtech Pharma, Inc. Derives d'azole substitues, compositions, et procedes d'utilisation
ATE419249T1 (de) 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
EP1740550A1 (fr) 2004-04-14 2007-01-10 Pfizer Limited Composes d'imidazole a liaison souphre pour le traitement du vih
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
DE602005008953D1 (de) 2004-05-21 2008-09-25 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
EP1807399A2 (fr) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Derives d'indole et de benzimidazole
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
MX2009005071A (es) 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Also Published As

Publication number Publication date
SV2009003325A (es) 2011-08-09
US20120189623A1 (en) 2012-07-26
TN2009000287A1 (en) 2010-12-31
AU2008205169A1 (en) 2008-07-17
DOP2009000169A (es) 2009-08-31
AR064760A1 (es) 2009-04-22
CO6561828A2 (es) 2012-11-15
US20080207589A1 (en) 2008-08-28
NI200900134A (es) 2010-07-05
EP2106399A2 (fr) 2009-10-07
WO2008086122A3 (fr) 2008-10-16
UA97821C2 (en) 2012-03-26
GT200900192A (es) 2010-06-24
AU2008205169B2 (en) 2012-02-02
SMAP200900065A (it) 2009-09-07
CA2674318A1 (fr) 2008-07-17
NZ577727A (en) 2012-03-30
BRPI0806264A2 (pt) 2011-08-30
MX2009007260A (es) 2009-07-10
JP2010515687A (ja) 2010-05-13
US20110003791A1 (en) 2011-01-06
ECSP099485A (es) 2009-08-28
SMP200900065B (it) 2010-09-10
CR10879A (es) 2009-08-05
WO2008086122A2 (fr) 2008-07-17
PE20081850A1 (es) 2009-02-05
EA200900924A1 (ru) 2009-12-30
CN101622247A (zh) 2010-01-06
US7820646B2 (en) 2010-10-26
GEP20125415B (en) 2012-03-12
TW200836722A (en) 2008-09-16
KR20090097210A (ko) 2009-09-15
CL2008000029A1 (es) 2008-04-04
HN2009001262A (es) 2012-01-09
ZA200904175B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA30959B1 (fr) Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu&#39;inhibiteurs de néprilysine
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
EA201100503A1 (ru) Глюкозидные производные и их применения
PT2058317E (pt) Derivado de éster do ácido aminofosfórico e modulador de receptor s1p contendo o mesmo como ingrediente activo
TN2009000085A1 (fr) Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
TW200728307A (en) Novel spirochromanone derivatives
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA33358B1 (fr) Arylpyridine en tant qu&#39;inhibiteurs de l&#39;aldostérone synthase
TW200612958A (en) Substituted imidazole derivatives
MA29688B1 (fr) Formulation d&#39;un inhibiteur de l&#39;agregation plaquettaire thienopyridine
ATE540932T1 (de) Hydantoin-derivate als antibakterielle wirkstoffe
UY32025A (es) Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones.
EP2613782A4 (fr) Dérivés d&#39;indazole utilisables en tant qu&#39;inhibiteurs de la voie erk
MX2009007482A (es) Agentes antiparasitarios.
MA35749B1 (fr) Dérivés nucléosidiques 4&#39;-azido, 3&#39;-fluoro substitués en tant qu&#39;inhibiteurs de la réplication de l&#39;arn du vhc
MA38112B1 (fr) Dérivés d&#39;imidazopyridazine en tant que modulateurs d&#39;un récepteur gabaa
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MA38559B1 (fr) Dérivés d&#39;imidazo-triazine utilisés comme inhibiteurs de la pde10
MX2009008028A (es) Agentes antiparasitarios.
UA103329C2 (ru) Соли соединений-ингибиторов вич
MA33828B1 (fr) Dérivés 8-hydroxyquinoline-7-carboxamide secondaires et leurs utilisations en tant qu&#39;agents antifongiques